MLTX MLTX
Company Profile ↓Company Overview
MLTX (MLTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -67.09% |
| 6 Months: | +14.18% |
| 3 Months: | +3.17% |
| 1 Month: | -8.36% |
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)41.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 71.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -94.11K | -32.68M | -6.27M | -15.94M | -17.65M | -14.77M | -12.93M | -13.19M | -12.98M | -19.82M | -30.58M | -43.11M | -47.48M | -60.70M | -71.43M | -70.02M |
| Net Income | -76.29K | -32.69M | -6.29M | -15.88M | -12.12M | -10.11M | -9.00M | -10.14M | -9.43M | -13.67M | -24.27M | -35.39M | -39.94M | -55.22M | -69.73M | -69.71M |
| Diluted EPS | - | -2.90 | -2.63 | -3.17 | -0.34 | -0.27 | -0.23 | -0.23 | -0.18 | -0.22 | -0.39 | -0.56 | -0.63 | -0.87 | -1.10 | -0.98 |
| R&D Expense | - | 29.87M | 669.53K | 10.45M | 11.40M | 9.02M | 7.42M | 8.70M | 7.59M | 13.01M | 23.66M | 35.74M | 36.46M | 49.76M | 60.63M | 54.52M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Income | -4.57M | -65.06M | -54.12M | -143.09M | -244.83M |
| Net Income | -4.54M | -49.97M | -36.01M | -118.94M | -227.32M |
| Diluted EPS | - | -1.70 | -0.73 | -1.89 | -3.53 |
| R&D Expense | - | 42.05M | 31.80M | 112.77M | 202.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Mar 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 116.63M | - | 9.68M | 76.84M | 526.54M | 477.93M | 424.43M |
| Total Equity | -2.52M | 106.51K | -11.65M | 48.90M | 495.68M | 446.82M | 304.48M |
| Cash & Equivalents | 1.34M | - | 8.04M | 39.51M | 451.17M | 180.43M | 334.52M |
| Long Term Debt | - | - | - | - | - | 0 | 74.10M |
| Total Liabilities | 4.15M | - | 21.33M | 8.08M | 13.05M | 24.54M | 119.95M |
| Current Liabilities | 125.18K | - | 21.09M | 7.67M | 9.97M | 22.46M | 45.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -611.07K | -55.89M | -42.78M | -116.59M | -196.01M |
| Investing Cash Flow | - | -32.34M | -25.18M | -205.60M | 202.99M |
| Financing Cash Flow | -58.06K | 119.69M | 479.70M | 51.31M | 146.00M |
| Capital Expenditure | - | -16.01K | -284.00K | -520.00K | -35.00K |
| Free Cash Flow | - | -55.91M | -43.06M | -117.11M | -196.04M |
| Share Buybacks | - | 0 | 0 | 50 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | 39.0% | -102.2% | -7.3% | -26.6% | -74.7% |
| ROCE % | 40.1% | -94.0% | -10.5% | -31.4% | -64.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLTX
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQnlIOGJJbzZZb002Mmxwc1pZZ3JNamJMZGg3OXpDYWNEOHFEVXZfNDY4LWMwRTdFMHBBSFdxXzBiSFAyRVFnQmg4a0NNd09fcGlJWEtHTVNlamNTU2ZxaWJ1N05rdHo2MlhJSDVEbERGdmFsQjRVMm02bGEwT2hHLUxzb3NnaDRjMThtR2…
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOVkttWU9KWHY3OUJkNUszQkdvWFRuc29yUnlGU0hLR2Q5WE1oMDl5Q1NJZl8zTm5wZHBRZ29VOURvM0xUZ3dlVmdhTWkxcU0yYmdkNlZTdDZ3bGFfY3VQdU5PZjhBeW1SRWVJZlpaUTgzTUU5Z3UyckpSTTBSM2d6MmN3RE5uTG5HUWJJV2…
Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNEtNMTRHMHZBb2RadXVlOWhUTDlidk8wMG1udVBmWVFDSHdVOGttVy00VWxqdlBjV21ZQ1dFVDQ5OWJFYklWRWZiWjZpb3E0SzdqUzBDWDVTSWlHY3RRZzFGbTAwVTJ1WEtXWEZlZnY2U1VNcHhLREhfS1NtYUNzU2gxcTZTaEN3dkROYz…
Why Did MLTX Stock Rise After-Hours Today? - TradingView
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNbmZOOGNRZVc4a01QdTRVT1hNWGtWOTBaVUJrLWpyM3piNXZzUTFEdmlEY0ZVYVdRTmw5bEFCSWtxeVNNRDE5Qmdzb0d2WnVqN0pLNFU1cnlxbFI5QXc4ZmVSRkFQc09KajdaYmZDYlhTZ29YODkwbnM2a09uUUhWSnJYTkhqWUNkT1BRTG…
Discipline and Rules-Based Execution in MLTX Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOUm16OF9LUVpMdjVxQ2IzeTJtcUp6eTI4N25PS0tOUk9KTUttZmNBWGplaVBKOVVnM2VsNGxzWG9TaE85bHFpcEthOFJnQ0tWQWYxUGVmV2h4ckZnclZCZlM3TFVWUzhoM1lnU0FHeEhoWkU1NkJyNDI0OUJpTGRGTWFVRFJlQ3JlSW1LLT…
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion (NASDAQ:MLTX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNMmNnd2dxYmJuUFlFNVFaY21QYXY5SF9YcFlXSDJWdHdVX3hRUGNiSTFOZDJQOTVsYkJySkR2U0xFLW1jVEFWMGJJQ0lfOXRPYUxJUk96eHVMd3ZfVkZZemJMcVhCT3d4dG5wUE1FbW5rQjdLMW4yNk1BRUNFOXRYRTA3dTI1S2RzejZPcE…
MLTX — Frequently Asked Questions
What is the current share price of MLTX?
As of 2026-08-05 17:25 PDT, MLTX trades at $17.55 on NASDAQ/NYSE. Its 52-week range is $6.24 to $61.99.
What is the P/E ratio of MLTX?
MLTX trades at a trailing price-to-earnings (P/E) ratio of -4.97.
What is the return on equity (ROE) of MLTX?
MLTX has a return on equity (ROE) of -74.66%. Its return on capital employed (ROCE) is -64.61%.
Is MLTX a good stock to buy?
This page provides a data-driven analysis of MLTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.